首页|多发性骨髓瘤患者达雷妥尤单抗药物不良反应与血药浓度的关系

多发性骨髓瘤患者达雷妥尤单抗药物不良反应与血药浓度的关系

扫码查看
目的 探究多发性骨髓瘤患者达雷妥尤单抗药物不良反应与血药浓度的关系.方法 选取2022年1月至2023年2月平煤神马医疗集团总医院收治的78例多发性骨髓瘤患者作为研究对象.患者均接受静脉输注达雷妥尤单抗治疗,观察并记录治疗后1周、2周、4周、8周的血药浓度、不良反应情况;采用Spearmen等级相关分析达雷妥尤单抗血药浓度与不良反应相关性;采用ROC曲线分析达雷妥尤单抗血药浓度监测对不良反应预测价值.结果 78例多发性骨髓瘤患者静脉输注达雷妥尤单抗治疗后1周、2周、4周、8周检测的血药浓度随治疗时间的延长血药浓度升高,差异有统计学意义(P<0.05).随治疗时间延长,第1、2、4、8周末多发性骨髓瘤不良反应患者达雷妥尤单抗浓度依次升高,差异有统计学意义(P<0.05).经Spearmen等级相关分析结果显示,第1、2、4、8周末,不良反应发生率明显上升,而达雷妥尤单抗血药浓度与不良反应呈正相关(P<0.05).经ROC曲线分析显示,达雷妥尤单抗血药浓度监测对不良反应发生具有一定预测作用,最佳截断值为4.03 mg/L,AUC为0.921(95%CI:0.859~0.984,P<0.05).结论 多发性骨髓瘤患者达雷妥尤单抗药物不良反应与血药浓度显著相关,达雷妥尤单抗血药浓度对是否发生药物不良反应具有预测价值,及时准确监测达雷妥尤单抗血药浓度有助于指导多发性骨髓瘤患者临床治疗.
Relationship between adverse drug reactions of daratumumab and blood drug concentration in patients with multiple myeloma
Objective To investigate the relationship between adverse drug reactions and plasma concentration of daratu-mumab in patients with multiple myeloma.Methods A total of 78 patients with multiple myeloma admitted to our hospi-tal from July 2021 to February 2023 were selected as the study subjects.The patients received intravenous infusion of daratumab,and the blood concentration and adverse reactions of 1 week,2 weeks,4 weeks and 8 weeks after treatment were observed and recorded.Spearmen grade correlation was used to analyze the correlation between daratumab blood concentration and adverse reactions.ROC curves were used to analyze the predictive value of daratumab blood concentra-tion monitoring on adverse reactions.Results The plasma concentrations detected in 78 patients with multiple myeloma after intravenous infusion of daratumab increased with the extension of treatment time at 1 week,2 weeks,4 weeks and 8 weeks(P<0.05).With the extension of treatment time,the concentration of daratumumab in patients with multiple my-eloma adverse reactions at the end of the 1st,2nd,4th and 8th weeks increased sequentially,and the difference was statis-tically significant(P<0.05).The results of Spearmen grade correlation analysis showed that the incidence of adverse reactions increased significantly in the 1st,2nd,4th and 8th weeks,while the blood concentration of daratumab was posi-tively correlated with adverse reactions(P<0.05).ROC curve analysis showed that daratumab blood concentration mo-nitoring had a certain predictive effect on the occurrence of adverse reactions,the best cut-off value was 4.03 mg/L,and the AUC was 0.921(95%CI:0.859~0.984,P<0.05).Conclusion The adverse drug reactions of daratumum-ab in patients with multiple myeloma are significantly correlated with blood concentrations,and the blood concentration of daratumumab has predictive value for whether adverse drug reactions occur,and timely and accurate monitoring of daratu-mumab blood concentration can help guide the clinical treatment of patients with multiple myeloma.

Multiple myelomaDaratumabAdverse reactionsBlood concentration

石军伟、高振甫

展开 >

平煤神马医疗集团总医院药学部,河南平顶山 467000

平煤神马医疗集团总医院脊柱骨科,河南平顶山 467000

多发性骨髓瘤 达雷妥尤单抗 不良反应 血药浓度

2024

医药论坛杂志
中华预防医学会,河南省医学情报研究所

医药论坛杂志

影响因子:0.47
ISSN:1672-3422
年,卷(期):2024.45(9)
  • 20